Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas

What Was Tested

Researchers studied Octreotide in this clinical trial publication.

The aim was to evaluate kinetic parameters in meningiomas before radiotherapy.

Why It Was Studied

Because biopsy has a high risk of hemorrhage and the findings of CT and MRI are often ambiguous, especially at the base of the skull, additional methods for the characterization of intracranial tumors are needed.

Meningiomas show high expression of the somatostatin receptor subtype 2 and thus offer the possibility of receptor-targeted imaging.

Who Took Part

The study group was 21 patients.

By PubMed's age tags, the people studied were adults, middle-aged adults, older adults and people over 80, both men and women.

Dynamic PET scans (3-dimensional mode; 28 frames; ordered-subsets expectation maximization reconstruction) were acquired for 21 patients (mean age +/- SD, 51 +/- 13 y) before radiotherapy during the 60 min after intravenous injection of 156 +/- 29 MBq of (68)Ga-DOTA-TOC.

For evaluation of the (68)Ga-DOTA-TOC kinetics, the vascular fraction (vB) and the rate constants (k1, k2, k3, and k4 [1/min]) were computed using a 2-tissue-compartment model.

How the Study Was Run

Furthermore, receptor binding (RB) (k1 - k1 x k2) and the ratios k1/k2 and k3/k4 were calculated.

What Was Measured

PubMed files the paper under topics including Brain, Gallium Radioisotopes, Meningeal Neoplasms, Meningioma, Metabolic Clearance Rate, Octreotide and Organ Specificity.

What This Means in Plain Language

This is a clinical trial of Octreotide in 21 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2005 (Journal of nuclear medicine : official publication, Society of Nuclear Medicine), a journal based in United States.

More context: the Octreotide compound page, all human trials.